To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.
USA115th CongressHR-6717| House
| Updated: 9/6/2018
Bobby L. Rush
Democratic Representative
Illinois
Energy and Commerce Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Depression Side Effect Labeling Awareness Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug that has an increased risk of suicide or depression to prominently display such risk.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Health
Administrative law and regulatory proceduresConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Mental health
To amend the Federal Food, Drug, and Cosmetic Act to require that the label of drugs with an increased risk of suicide or depression present such increased risk prominently, and for other purposes.
USA115th CongressHR-6717| House
| Updated: 9/6/2018
Depression Side Effect Labeling Awareness Act of 2018 This bill amends the Federal Food, Drug, and Cosmetic Act to require the label of a drug that has an increased risk of suicide or depression to prominently display such risk.
View Full TextSuggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in House
Referred to the House Committee on Energy and Commerce.
Bobby L. Rush
Democratic Representative
Illinois
Energy and Commerce Committee
Health
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresConsumer affairsDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)Mental health